Cooper Companies Inc (NYSE:COO) – Analysts at Northcoast Research upped their Q1 2019 EPS estimates for Cooper Companies in a report issued on Tuesday, February 19th. Northcoast Research analyst D. Keiser now forecasts that the medical device company will post earnings per share of $2.52 for the quarter, up from their prior estimate of $2.48. Northcoast Research also issued estimates for Cooper Companies’ Q4 2019 earnings at $3.15 EPS and FY2019 earnings at $11.71 EPS.
Cooper Companies (NYSE:COO) last posted its quarterly earnings data on Thursday, December 6th. The medical device company reported $2.87 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $2.96 by ($0.09). The firm had revenue of $651.50 million for the quarter, compared to the consensus estimate of $645.25 million. Cooper Companies had a net margin of 5.52% and a return on equity of 17.70%. The business’s revenue was up 16.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.65 earnings per share.
Several other research firms have also recently issued reports on COO. Oppenheimer set a $282.00 price objective on Cooper Companies and gave the company a “hold” rating in a research report on Friday, December 7th. KeyCorp reduced their price objective on Cooper Companies from $298.00 to $296.00 and set an “overweight” rating for the company in a research note on Friday, December 7th. Wells Fargo & Co upped their target price on shares of Cooper Companies from $295.00 to $305.00 and gave the stock an “outperform” rating in a report on Friday, December 7th. Jefferies Financial Group upped their target price on shares of Cooper Companies to $305.00 and gave the stock a “buy” rating in a report on Friday, December 7th. Finally, William Blair reissued an “outperform” rating on shares of Cooper Companies in a report on Saturday, January 12th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $289.44.
Shares of COO opened at $284.62 on Thursday. The company has a current ratio of 2.03, a quick ratio of 1.16 and a debt-to-equity ratio of 0.60. Cooper Companies has a 52 week low of $216.47 and a 52 week high of $288.51. The company has a market capitalization of $13.98 billion, a PE ratio of 24.75, a P/E/G ratio of 2.23 and a beta of 0.88.
The company also recently disclosed a semiannual dividend, which was paid on Friday, February 8th. Shareholders of record on Tuesday, January 22nd were issued a $0.03 dividend. The ex-dividend date was Friday, January 18th. This represents a yield of 0.02%. Cooper Companies’s payout ratio is 0.52%.
In related news, Director Allan E. Rubenstein bought 348 shares of the business’s stock in a transaction dated Monday, December 10th. The stock was acquired at an average price of $241.59 per share, with a total value of $84,073.32. Following the completion of the purchase, the director now directly owns 4,524 shares of the company’s stock, valued at $1,092,953.16. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.70% of the stock is owned by insiders.
Several hedge funds have recently modified their holdings of COO. Essex Savings Bank purchased a new stake in Cooper Companies during the 4th quarter worth approximately $25,000. Certified Advisory Corp purchased a new stake in Cooper Companies in the 4th quarter worth $25,000. Executive Wealth Management LLC purchased a new stake in Cooper Companies in the 4th quarter worth $34,000. Financial Gravity Companies Inc. bought a new position in shares of Cooper Companies during the 4th quarter valued at about $46,000. Finally, Rehmann Capital Advisory Group boosted its holdings in shares of Cooper Companies by 24.3% during the 4th quarter. Rehmann Capital Advisory Group now owns 220 shares of the medical device company’s stock valued at $56,000 after purchasing an additional 43 shares during the last quarter.
Cooper Companies Company Profile
The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.
Featured Article: How to Invest in a Bull Market
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.